Malignant Neoplasm — Trials

Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 20,108
Recruiting: 10,888
Ph III recruiting: 1,278
Growth YoY: +12.8%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11,158)

clinicaltrialsPublishedShowing 2,451–2,500 of 2,527 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03899857	Pembrolizumab for Newly Diagnosed Glioblastoma(PERGOLA)	active not recruiting	Phase 2	56	University of ZurichOTHER	1	May 8, 2024	clinicaltrials
NCT05033756	Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO(COMPRENDO)	active not recruiting	Phase 2	11	Institut fuer Frauengesundheit